IL-17A has demonstrated differential effects in PS and IBD: in psoriasis, it is overexpressed in baseline psoriatic skin lesions as a primary driver of the disease pathology, while in IBD, it promotes the activation of regulatory pathways and confers protection in the gastrointestinal tract51. Here, IL17A is linked to psoriasis.